Etoricoxib is a class of selective NSAIDs approved by the Medicines Agency (EMEA) for the acute and chronic treatment of signs and symptoms of OA and RA, treatment of ankylosing spondy-litis (AS), treatment of acute gouty arthritis, relief of acute and chronic pain, and treatment of primary dysmenorrhea.This study identifies the types of DRPs in the form of excessive doses in the prescription of etoricoxib, on an outpatient basis in all polyclinics in one of the hospitals in Banyuasin Regency in the January 2022 Period. The development of this study is expected to provide information on the description of the incidence of DRPs in the form of over-dosage in drug prescribing on an outpatient basis in all polyclinics in one of the hospitals in Banyuasin Regency. This study was an analytic study using a cross-sectional research design to determine the influence of risk factors on the incidence of overdoses etoricoxib therapy in polyclinic outpatients at one of the hospitals in Banyuasin Regency in Januari 2022 .The results showed an relationship between age, multipathology and polypharmacy on the incidence of excessive doses of etoricoxib in outpatient polyclinics (p value = 0.001) and pharmacist intervention have a relationship to Reduce the Incidence of Overdose of Etoricoxib in Outpatient Polyclinic Setting.